Theratechnologies files preliminary prospectus for US IPO and further Canadian issuance

On February 22, 2011, Theratechnologies Inc. (TSX: TH) announced that it had filed a preliminary short form base PREP prospectus in connection with a proposed cross-border offering of approximately 11 million common shares, with an over-allotment option of 15%. This offering will be Theratechnologies' initial public offering in the United States. The offering was made through a syndicate of underwriters comprised of Jefferies & Company, Inc., Stifel, Nicolaus & Company, Inc., RBC Capital Markets, LLC, BMO Capital Markets Corporation, Desjardins Securities International Inc. and NBF Securities (USA) Corp. Theratechnologies' common shares are being offered in Canada by Stifel Nicolaus Canada Inc., RBC Dominion Securities Inc., BMO Nesbitt Burns Inc., Desjardins Securities Inc. and National Bank Financial Inc. Theratechnologies plans to use the net proceeds from the offering to advance its clinical program relating to muscle wasting in chronic obstructive pulmonary disease (COPD), to complete its new formulation of EGRIFTA™ and tesamorelin, to continue research and development of novel GRF peptides, for potential acquisitions, and for working capital and other general corporate purposes. Theratechnologies was advised by a team from Fasken Martineau comprised of Robert Girard, Frédéric Boucher, Caitlin Rose, Monica Dingle and Jimmy Triassi (corporate and securities) and Serge Gloutnay (tax).